These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12413244)

  • 21. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
    Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
    Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive Bayesian randomized trials: realizing their potential.
    Pullenayegum EM
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sequential procedure for comparing two experimental treatments with a control.
    Vincent E; Todd S; Whitehead J
    J Biopharm Stat; 2002 May; 12(2):249-65. PubMed ID: 12413243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole.
    Paillisse C; Lacomblez L; Dib M; Bensimon G; Garcia-Acosta S; Meininger V
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Mar; 6(1):37-44. PubMed ID: 16036424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
    Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.
    Riviere M; Meininger V; Zeisser P; Munsat T
    Arch Neurol; 1998 Apr; 55(4):526-8. PubMed ID: 9561981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current clinical trials in amyotrophic lateral sclerosis.
    Bhatt JM; Gordon PH
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1197-207. PubMed ID: 17685869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Glutamate antagonist].
    Shindo M
    No To Shinkei; 1998 Jul; 50(7):597-605. PubMed ID: 9739517
    [No Abstract]   [Full Text] [Related]  

  • 31. Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.
    Whitehead J; Cleary F; Turner A
    Stat Med; 2015 May; 34(12):2048-61. PubMed ID: 25765252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study.
    Moura MC; Novaes MR; Eduardo EJ; Zago YS; Freitas Rdel N; Casulari LA
    PLoS One; 2015; 10(10):e0141500. PubMed ID: 26517122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Riluzole for amyotrophic lateral sclerosis.
    Drug Ther Bull; 1997 Feb; 35(2):11-2. PubMed ID: 9282413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Bayesian adaptive blinded sample size adjustment method for risk differences.
    Hartley AM
    Pharm Stat; 2015; 14(6):488-514. PubMed ID: 26403845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.
    Howard G; Coffey CS; Cutter GR
    Stroke; 2005 Jul; 36(7):1622-3. PubMed ID: 15947275
    [No Abstract]   [Full Text] [Related]  

  • 37. Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective.
    Xu Q; Cho J; Ben Chaouch Z; Lo AW
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):281-288. PubMed ID: 36287176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis.
    Turner MR; Bakker M; Sham P; Shaw CE; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):15-21. PubMed ID: 12061944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches.
    Smania G; Baiardi P; Ceci A; Cella M; Magni P
    CPT Pharmacometrics Syst Pharmacol; 2016 Aug; 5(8):402-10. PubMed ID: 27530374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.